New injection aims to retrain immune cells to fight arthritis

NCT ID NCT07349420

Completed Disease control Sponsor: S.LAB (SOLOWAYS) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tested a new drug called EF-M2 (Immutalon) in 48 adults with moderate-to-severe rheumatoid arthritis. The drug is designed to shift immune cells from a pro-inflammatory to an anti-inflammatory state. Participants received injections for 4 weeks, and researchers monitored safety and signs of immune changes. The goal is to see if this approach can control disease without needing lifelong medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EF-M2 (Immutalon), a drug injected under the skin to shift immune cells toward an anti-inflammatory state
What this could lead to: If it works, this could point toward a new way to control rheumatoid arthritis by calming overactive immune cells without long-term side effects.
What could go wrong: This is a very early, small trial (48 people) focused on safety, not proof of effectiveness. The drug may not work or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

Contacts and locations

Locations

Center for New Medical Technologies

Novosibirsk, Novosibirsk Oblast, 630090, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.